Market Place
Sourcing Support
Celldex To Present At Upcoming Investor Conference
13 Apr 2026 //
GLOBENEWSWIRE
Celldex Closes Offering with Full Exercise of Underwriters`
06 Apr 2026 //
GLOBENEWSWIRE
Celldex Announces Proposed Public Offering Of Common Stock
01 Apr 2026 //
GLOBENEWSWIRE
Celldex Unveils 2025 Financials And Corporate Progress
25 Feb 2026 //
GLOBENEWSWIRE
Celldex Unveils Q3 2025 Financials & Corporate Progress
10 Nov 2025 //
GLOBENEWSWIRE
Celldex Names Teri Lawver as Chief Commercial Officer
10 Nov 2025 //
GLOBENEWSWIRE
Celldex To Present At Upcoming Investor Conferences
07 Nov 2025 //
GLOBENEWSWIRE
Celldex to Speak at Morgan Stanley`s Global Health Conference
09 Sep 2025 //
GLOBENEWSWIRE
Celldex Therapeutics Elects Denice Torres to Board of Directors
06 Jun 2025 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Upcoming Investor Conferences
04 Mar 2025 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Upcoming Investor Conferences
11 Nov 2024 //
GLOBENEWSWIRE
Celldex Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Celldex`s Anti-cKIT Antibody Reduces Chronic Hives In Phase 2 Trial
30 Jul 2024 //
FIERCE BIOTECH
Celldex Reports Positive Phase 2 Results For Barzolvolimab In Urticaria
29 Jul 2024 //
GLOBENEWSWIRE
Celldex Initiates Phase 3 Program For Barzolvolimab In Urticaria
16 Jul 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Jefferies Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
Celldex Reports Q1 2024 Results, Corporate Update
06 May 2024 //
GLOBENEWSWIRE
Celldex to Participate in the Leerink Partners Global Biopharma Conference
08 Mar 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
05 Mar 2024 //
YAHOO FINANCE
Celldex Therapeutics Announces Closing of Public Offering of Common Stock
05 Mar 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at TD Cowens 44th Annual Health Care Conference
05 Mar 2024 //
GLOBENEWSWIRE
Celldex Announces Pricing of Upsized $400M Public Offering of Common Stock
29 Feb 2024 //
PRESS RELEASE
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
28 Feb 2024 //
GLOBENEWSWIRE
Celldex’s CSU drug could challenge a Novartis candidate after PhII
27 Feb 2024 //
ENDPTS
Celldex Reports Fourth Quarter and Year End 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Celldex to Participate in Guggenheim Healthcare Talks 6th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
27 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
07 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
07 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Positive Results from Barzolvolimab Phase 2 Study
06 Nov 2023 //
PRESS RELEASE
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab
06 Nov 2023 //
GLOBENEWSWIRE
Celldex laces up next to Big Pharmas with chronic hive drug
06 Nov 2023 //
FIERCE BIOTECH
Celldex Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
25 Sep 2023 //
GLOBENEWSWIRE
Celldex Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Celldex Reports 1Q FYR 2023 and Provides Corporate Update
04 May 2023 //
GLOBENEWSWIRE
Celldex to Present at H.C. Wainwright Autoimmune Virtual Conference
29 Mar 2023 //
GLOBENEWSWIRE
Celldex Reports Fourth Quarter and Year End 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Celldex fleshes out case for Xolair challenger in chronic hives
28 Feb 2023 //
ENDPTS
Celldex Therapeutics Announces Appointment of Rita Jain to Board of Directors
16 Feb 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
15 Feb 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study
06 Dec 2022 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab
02 Dec 2022 //
GLOBENEWSWIRE
Celldex to Participate in Upcoming November Investor Conferences
10 Nov 2022 //
GLOBENEWSWIRE
Celldex Reports 3Q 2022 Financial Results and Provides Corporate Update
09 Nov 2022 //
GLOBENEWSWIRE
Research Analysts Offer Predictions for Celldex, Q3 2022 Earnings
13 Oct 2022 //
MARKETBEAT
Celldex Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab
21 Jul 2022 //
GLOBENEWSWIRE
Celldex offers a positive early readout for their rival drug
01 Jul 2022 //
ENDPTS
Celldex Tx Presents Positive Interim Data from Barzolvolimab PIb Study in CSU
30 Jun 2022 //
GLOBENEWSWIRE
Celldex Announces First Patient Dosed in PII Study of Barzolvolimab
21 Jun 2022 //
GLOBENEWSWIRE
Celldex Announces Two New Appointments to its Board of Directors
16 Jun 2022 //
GLOBENEWSWIRE
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
06 Jun 2022 //
GLOBENEWSWIRE
Celldex Announces Acceptance of Abstract for Barzolvolimab PIb Results in CSU
19 May 2022 //
GLOBENEWSWIRE
Celldex Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 Feb 2022 //
GLOBENEWSWIRE
Celldex Presents Positive PC Data from PD-1/ILT4 Bispecific Antibody Program
12 Nov 2021 //
GLOBENEWSWIRE
Celldex Presents Positive Data on Symptom Control and Quality of CDX-0159
28 Sep 2021 //
GLOBENEWSWIRE
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results
23 Sep 2021 //
GLOBENEWSWIRE
